Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 15/20 | 0.62 |
| ▸ | MAOA | P21397 | 3/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | FBP1 | P09467 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101470 | 1.00 | P4HB (0.62) | P4HBMAOAMAOBFBP1 | |
| SCHEMBL8497675 | 0.86 | P4HB (0.66) | P4HBMAOAMAOBFBP1 | |
| SCHEMBL7339707 | 0.86 | P4HB (0.66) | P4HBMAOAMAOBFBP1 | |
| SCHEMBL30745014 | 0.85 | P4HB (0.64) | P4HBMAOAMAOBFBP1 | |
| SCHEMBL1225943 | 0.85 | P4HB (0.64) | P4HBMAOAMAOBFBP1 | |
| SCHEMBL1225940 | 0.85 | P4HB (0.64) | P4HBMAOAMAOBFBP1 | |
| SCHEMBL30912094 | 0.85 | P4HB (0.64) | P4HBMAOAMAOBFBP1 | |
| SCHEMBL6977108 | 0.83 | P4HB (0.62) | P4HBMAOAMAOBFBP1 | |
| Hydrochloric Acid SCHEMBL4101473 | 0.83 | P4HB (0.62) | P4HBMAOAMAOBFBP1 | |
| SCHEMBL6977115 | 0.83 | P4HB (0.62) | P4HBMAOAMAOBFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114230519-B | Pleuromutilin cinnamate compounds with drug-resistant bacteria resisting activity, and synthetic method and application thereof | 西咸新区沣厚原创医药科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-114230519-A | Pleuromutilin cinnamate compounds with drug-resistant bacterium resisting activity and synthesis method and application thereof | 陕西科技大学 | 2022-03-25 | — | — | CN | disclosed |
| EP-1982716-B1 | NOVEL HISTIDINE DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8236844-B2 | Histidine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20090149658-A1 | Novel Histidine Derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-1982716-A1 | NOVEL HISTIDINE DERIVATIVE | Nippon Zoki Pharmaceutical Co. Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| WO-2004046122-A2 | BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE ACID DERIVATIVES AND THEIR USE AS HEPARANASE INHIBITORS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-06-03 | — | — | WO | disclosed |
| EP-0934265-B1 | AMIDINOPHENYL-PYRROLIDINES, -PYRROLINES, AND -ISOXAZOLIDINES AND DERIVATIVES THEREOF | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6057342-A | INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR XA, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME AS ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | DUPONT PHARMACEUTICAL CO. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0934265-A1 | AMIDINOPHENYL-PYRROLIDINES, -PYRROLINES, AND -ISOXAZOLIDINES AND DERIVATIVES THEREOF | Du Pont Pharmaceuticals Company (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998006694-A1 | AMIDINOPHENYL-PYRROLIDINES, -PYRROLINES, AND -ISOXAZOLIDINES AND DERIVATIVES THEREOF | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0343777-B1 | Thio-substituted aromatic alcohols, preparation, intermediates and use | LILLY INDUSTRIES LTD (GB) | 1994-06-15 | — | — | EP | disclosed |
| US-5021441-A | Halo, thio, hydroxy-substituted alkyl benzenes containing mono-or dicarboxy or tetrapolyl groups, leukotriene antagonist antiallergens, cardiovascular disorders | LILLY INDUSTRIES LIMITED (GB) | 1991-06-04 | — | — | US | disclosed |
| EP-0186426-B1 | TETRAZOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USE | Lilly Industries Limited (GB) | 1990-09-12 | — | — | EP | disclosed |
| EP-0343777-A1 | Thio-substituted aromatic alcohols, preparation, intermediates and use | LILLY INDUSTRIES LIMITED (GB) | 1989-11-29 | — | — | EP | disclosed |
| EP-0186426-A2 | Tetrazolyl compounds and their pharmaceutical use | Lilly Industries Limited (GB) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149658-A1 | Novel Histidine Derivatives | HRH4, HNMT, HRH3 | P4HB 2532/4885MAOA 730/4885MAOB 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.